Sentiment Trading

Hansa Biopharma AB reports positive clinical results for its immunomodulatory enzyme imlifidase in combination with gene therapy for Duchenne muscular dystrophy treatment.

Hansa Biopharma AB reports positive results from a study using imlifidase to treat Duchenne muscular dystrophy, paving the way for improved gene therapy efficacy.